Larissa K Dill Selected Research

N,N',N'- tris(2- hydroxyethyl)- 1,3,5- benzenetricarboxamide

9/2021	Corrigendum to "Acute treatment with TrkB agonist LM22A-4 confers neuroprotection and preserves myelin integrity in a mouse model of pediatric traumatic brain injury" [Experimental Neurology 339 (2021): 113652].
1/2021	Acute treatment with TrkB agonist LM22A-4 confers neuroprotection and preserves myelin integrity in a mouse model of pediatric traumatic brain injury.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Larissa K Dill Research Topics

Disease

3	Traumatic Brain Injuries (Traumatic Brain Injury) 09/2021 - 10/2019
2	Infections 01/2022 - 03/2021
1	Inflammation (Inflammations) 01/2021
1	Edema (Dropsy) 01/2021
1	Gliosis 01/2021
1	Memory Disorders (Memory Loss) 01/2021
1	Epilepsy (Aura) 10/2019
1	Brain Edema (Cerebral Edema) 10/2019
1	Neuroinflammatory Diseases 10/2019

Drug/Important Bio-Agent (IBA)

2	LipopolysaccharidesIBA 01/2022 - 03/2021
2	N,N',N'- tris(2- hydroxyethyl)- 1,3,5- benzenetricarboxamideIBA 09/2021 - 01/2021
1	Ion Channels (Ion Channel)IBA 01/2021
1	Serotonin (5 Hydroxytryptamine)IBA 01/2021
1	Anti-Anxiety Agents (Anxiolytics)IBA 01/2021
1	HMGB1 Protein (HMG1)IBA 10/2019
1	Proteins (Proteins, Gene)FDA Link 10/2019